Status: Recruiting
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
Participants needed: 60
Trial details
Phase: Phase 2Age: 12-39Biological sex: AllType: InterventionalSponsor: Nationwide Children's HospitalUpdated: May 15, 2026Locations: 20
Eligibility criteria
Patients must be ≥ 12 months and ≤ 39 years of age at the time of study enrollme... [+19]
Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosupp... [+40]